Orionis Biosciences is a life sciences company pioneering conditionally active immunotherapies (A-Kines) and molecular glue drug discovery (AlloGlues) for cancer and immunology. The company has research collaborations with Novartis and Genentech/Roche, and is advancing internal programs in oncology and immunology.
Company Info
Funding & Investor Relations
None publicly disclosed; private biotech with strong pharma partnership revenue.
Upcoming Milestones & Key Dates
Nomination of first development candidate from Novartis collaboration
Phase 1 clinical updates for ORB-011 and ORB-021 A-Kine programs
Clinical Development Pipeline
Recent News
Novartis and Orionis Biosciences have signed a second molecular glue degrader collaboration, paying $40M upfront to expand an existing partnership focused on induced proximity therapeutics for cancer and other diseases.
Novartis signed a second molecular glue discovery deal with Orionis Biosciences, paying $40M upfront and committing up to $1.4B in milestones, deepening a partnership that began in 2024.
Leadership Team
Careers & Job Openings